{"id":451295,"date":"2021-03-04T16:18:14","date_gmt":"2021-03-04T21:18:14","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=451295"},"modified":"2021-03-04T16:18:14","modified_gmt":"2021-03-04T21:18:14","slug":"onconova-therapeutics-to-provide-corporate-update-and-full-year-2020-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-provide-corporate-update-and-full-year-2020-financial-results\/","title":{"rendered":"Onconova Therapeutics to Provide Corporate Update and Full Year 2020 Financial Results"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">\n        <em>Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time on Thursday, March 11, 2021<\/em><br \/>\n        \n      <\/p>\n<p align=\"justify\">NEWTOWN, Pa., March  04, 2021  (GLOBE NEWSWIRE) &#8212; Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will release its year-end 2020 financial results on Thursday, March 11, 2021, after the market closes. Management will host a conference call and live webcast at 4:30 p.m. ET on the same day to discuss these results and provide an update on its pipeline programs.<\/p>\n<p align=\"justify\">Interested parties who wish to participate in the conference call may do so by dialing (855) 428-5741 for domestic and (210) 229-8823 for international callers and using conference ID 3863774. Those interested in listening to the conference call live via the internet may do so by visiting the investors\u2019 page of the company&#8217;s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bM8WknyGeRvviXJspk7J8rZmq-5TwsdsojTBPM_DcKi_dpDwgpoXMzMYS-O_62IUYD8hCKznQnnYWm-LhP4Irw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.onconova.com<\/a> and clicking on the webcast link.<\/p>\n<p align=\"justify\">A webcast replay will be available on the Onconova website for 90 days following the call by visiting the investor page of the company&#8217;s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bM8WknyGeRvviXJspk7J8qbHytImta3obdccKkv4vSUO2aqd3F5dHH841DWzJprRtSy326ZKwJTeuYDnzo-PHw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.onconova.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>About Onconova Therapeutics, Inc. <\/strong><br \/>\n        <br \/>Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.<\/p>\n<p align=\"justify\">Onconova\u2019s novel, proprietary multi-kinase inhibitor ON 123300 is planned to begin a dose-escalation and expansion Phase 1 trial in the U.S. in the first half of 2021, and a dose-escalation and expansion Phase 1 trial is currently underway in China.<\/p>\n<p align=\"justify\">Onconova\u2019s product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab. In addition, Onconova has commenced preclinical work investigating rigosertib in COVID-19.<\/p>\n<p align=\"justify\">For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bM8WknyGeRvviXJspk7J8tcLQmM_EI3jCFiB89TGkof7TOc5J4XNMcTNaeytQ5VuHG7Zk_8w3c4f4sU_hc9QbQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.onconova.com<\/a>.<\/p>\n<p>\n        <strong>Contact information<\/strong>\n      <\/p>\n<p>\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>Avi Oler<br \/>Onconova Therapeutics, Inc.<br \/>267-759-3680<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xWdc1OQzaOjSGjM1RkIVkN9ns4IbVttSoE0AhRy2y6LvQDGn45nH8zHjTF9nsyJwJdmkqsrRngLwG8zcKi63kw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">ir@onconova.us<\/a>\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ptJfJPFOzPIlnD2w1KOmQ5h8MnEMGSbguxd6pACD9WWRKvsqyq_cSkJ8e9ICOWqbl0AG5DAC6hNHQtkuzjPY_zrxwHwrUAANBRcDuKGSijugd2ikZziAWog3CHfLaUbZ\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/www.onconova.com\/contact\/<\/a><\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>LHA Investor Relations<br \/>Kim Sutton Golodetz<br \/>212-838-3777<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sSgArS-jqzlQn96Vvdk-MUXkdOuo7GG7j7Z5WEs332GFGd6MFpkzGfhh2LmwxDMVJD4pKhj_8An_IiPqaNgz1yNgRH-Hh1zIP-M-uAWKpkI=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">kgolodetz@lhai.com<\/a>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDg0OSM0MDQ5NDQzIzIwMDU2MTU=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/994631e7-4ce5-48ad-bf54-5c3af6d1450b\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time on Thursday, March 11, 2021 NEWTOWN, Pa., March 04, 2021 (GLOBE NEWSWIRE) &#8212; Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will release its year-end 2020 financial results on Thursday, March 11, 2021, after the market closes. Management will host a conference call and live webcast at 4:30 p.m. ET on the same day to discuss these results and provide an update on its pipeline programs. Interested parties who wish to participate in the conference call may do so by dialing (855) 428-5741 for domestic and (210) 229-8823 for international callers &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-provide-corporate-update-and-full-year-2020-financial-results\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Onconova Therapeutics to Provide Corporate Update and Full Year 2020 Financial Results&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-451295","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Onconova Therapeutics to Provide Corporate Update and Full Year 2020 Financial Results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-provide-corporate-update-and-full-year-2020-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Onconova Therapeutics to Provide Corporate Update and Full Year 2020 Financial Results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time on Thursday, March 11, 2021 NEWTOWN, Pa., March 04, 2021 (GLOBE NEWSWIRE) &#8212; Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will release its year-end 2020 financial results on Thursday, March 11, 2021, after the market closes. Management will host a conference call and live webcast at 4:30 p.m. ET on the same day to discuss these results and provide an update on its pipeline programs. Interested parties who wish to participate in the conference call may do so by dialing (855) 428-5741 for domestic and (210) 229-8823 for international callers &hellip; Continue reading &quot;Onconova Therapeutics to Provide Corporate Update and Full Year 2020 Financial Results&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-provide-corporate-update-and-full-year-2020-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-04T21:18:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDg0OSM0MDQ5NDQzIzIwMDU2MTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-to-provide-corporate-update-and-full-year-2020-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-to-provide-corporate-update-and-full-year-2020-financial-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Onconova Therapeutics to Provide Corporate Update and Full Year 2020 Financial Results\",\"datePublished\":\"2021-03-04T21:18:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-to-provide-corporate-update-and-full-year-2020-financial-results\\\/\"},\"wordCount\":342,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-to-provide-corporate-update-and-full-year-2020-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDg0OSM0MDQ5NDQzIzIwMDU2MTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-to-provide-corporate-update-and-full-year-2020-financial-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-to-provide-corporate-update-and-full-year-2020-financial-results\\\/\",\"name\":\"Onconova Therapeutics to Provide Corporate Update and Full Year 2020 Financial Results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-to-provide-corporate-update-and-full-year-2020-financial-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-to-provide-corporate-update-and-full-year-2020-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDg0OSM0MDQ5NDQzIzIwMDU2MTU=\",\"datePublished\":\"2021-03-04T21:18:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-to-provide-corporate-update-and-full-year-2020-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-to-provide-corporate-update-and-full-year-2020-financial-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-to-provide-corporate-update-and-full-year-2020-financial-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDg0OSM0MDQ5NDQzIzIwMDU2MTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDg0OSM0MDQ5NDQzIzIwMDU2MTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconova-therapeutics-to-provide-corporate-update-and-full-year-2020-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Onconova Therapeutics to Provide Corporate Update and Full Year 2020 Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Onconova Therapeutics to Provide Corporate Update and Full Year 2020 Financial Results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-provide-corporate-update-and-full-year-2020-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"Onconova Therapeutics to Provide Corporate Update and Full Year 2020 Financial Results - Market Newsdesk","og_description":"Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time on Thursday, March 11, 2021 NEWTOWN, Pa., March 04, 2021 (GLOBE NEWSWIRE) &#8212; Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will release its year-end 2020 financial results on Thursday, March 11, 2021, after the market closes. Management will host a conference call and live webcast at 4:30 p.m. ET on the same day to discuss these results and provide an update on its pipeline programs. Interested parties who wish to participate in the conference call may do so by dialing (855) 428-5741 for domestic and (210) 229-8823 for international callers &hellip; Continue reading \"Onconova Therapeutics to Provide Corporate Update and Full Year 2020 Financial Results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-provide-corporate-update-and-full-year-2020-financial-results\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-04T21:18:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDg0OSM0MDQ5NDQzIzIwMDU2MTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-provide-corporate-update-and-full-year-2020-financial-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-provide-corporate-update-and-full-year-2020-financial-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Onconova Therapeutics to Provide Corporate Update and Full Year 2020 Financial Results","datePublished":"2021-03-04T21:18:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-provide-corporate-update-and-full-year-2020-financial-results\/"},"wordCount":342,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-provide-corporate-update-and-full-year-2020-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDg0OSM0MDQ5NDQzIzIwMDU2MTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-provide-corporate-update-and-full-year-2020-financial-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-provide-corporate-update-and-full-year-2020-financial-results\/","name":"Onconova Therapeutics to Provide Corporate Update and Full Year 2020 Financial Results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-provide-corporate-update-and-full-year-2020-financial-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-provide-corporate-update-and-full-year-2020-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDg0OSM0MDQ5NDQzIzIwMDU2MTU=","datePublished":"2021-03-04T21:18:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-provide-corporate-update-and-full-year-2020-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-provide-corporate-update-and-full-year-2020-financial-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-provide-corporate-update-and-full-year-2020-financial-results\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDg0OSM0MDQ5NDQzIzIwMDU2MTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDg0OSM0MDQ5NDQzIzIwMDU2MTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconova-therapeutics-to-provide-corporate-update-and-full-year-2020-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Onconova Therapeutics to Provide Corporate Update and Full Year 2020 Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/451295","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=451295"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/451295\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=451295"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=451295"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=451295"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}